Autumn Vaca, LMFTA Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1400 Willow Ln, North Wilkesboro, NC 28659 Phone: 336-667-5151 |
Jayna Jeanette Lattimore, LMFTA Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1400 Willow Ln, North Wilkesboro, NC 28659 Phone: 336-667-5151 Fax: 336-667-5048 |
News Archive
Two female Democrats walked out of a House oversight committee hearing on the contraceptive coverage rule Thursday morning, accusing Chairman Darrell Issa of manipulating committee rules to block female witnesses from testifying. "What I want to know is, where are the women?" asked Rep. Carolyn Maloney before walking out. "I look at this panel of witnesses, and I don't see one single individual representing the tens of millions of women across the country who want and need insurance coverage for basic preventive health care services, including family planning."
Certain middle-aged and older adults, especially women who tend to disengage from difficult tasks and goals after they retire, may be at greater risk of cognitive decline as they age, according to research published by the American Psychological Association.
Hundreds of home care and hospice providers will arrive in that nation's capitol to keep the fight alive for the critical, high-value, high-quality care that is delivered every day to some of the nation's most vulnerable individuals.
HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.
ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.
› Verified 2 days ago